All News

myositis.jpg

Checkpoint Inhibitors: Who Gets Myocarditis?

d RheumNow

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

Read Article
AS.Sacroiliitis.CT_.SpA_.jpg

Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)

d Jack Cush, MD

The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).  

Read Article
guidelines.jpg (keep)

ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

d Jack Cush, MD

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axi

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

d Jack Cush, MD

Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.

Read Article
US.MTP1_.synovitis.PD_.gout_.jpg

A Multidimensional Definition of Remission

d Jack Cush, MD

A study from Leeds suggests 'multi-dimensional remission' (MDR) can be seen in one-third of RA patients achieving DAS28-remission; such patients have better patient-reported outcome measures, making it an optimal goal, especially from a patient's perspective.

Read Article

Osteoporosis Tx: Good for Bones, but Not for Cutting Death Risk

d RheumNow

Osteoporosis treatments were not linked with reduced overall mortality, according to a meta-analysis of placebo-controlled trial data.

Read Article
FDA has approved Taltz (ixekizumab) use in Active Ankylosing Spondylitis (Axial Spondyloarthritis). IXE previously approved for psoriasis & PsA. Recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. https://t.co/S8zwuYuK2H

Links:

Dr. John Cush RheumNow ( View Tweet)

CLE deserves a specialty approach, with more education and people (derms & Rheums) dedicated to it's managemment https://t.co/VDH4ksDRW4

Links:

Dr. John Cush RheumNow ( View Tweet)

@ClinRheumatol Whoa...this an 11 patient uncontrolled report - not a study and certainly NOT evidence that abatacept works in Sjogrens. ABA is not included in guidelines for, and not approved for use in Sjogrens. Journals who promote$$$ their publications should not be interpreting results!

Dr. John Cush RheumNow ( View Tweet)

PBMs: Driving Up Costs and Lowering Quality Care in America https://t.co/4gQr9L5Ate

Links:

ATAP ATAPAdvocates ( View Tweet)

European Study of 24,195 axSpA pts shows that 1st TNFi resulted in 27% ASDAS inactive disease @6 months & 59% achieved BASDAI <40; 80% continued Rx after 1 year. 1178 patients w/ non-radiographic axSpA had lower 12-mos retention (73%) https://t.co/KJn5eD6wWw

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Upadacitinib Approved, ULT prevents erosions, JIA pregnancies, MDA-5 outcomes & more. Watch it here>> https://t.co/kzu32MMmRL or listen to the PODCAST on iTunes or SoundCloud>> https://t.co/Ewi3Kc6lta

Links:

Dr. John Cush RheumNow ( View Tweet)

https://t.co/Es3nquURHJ is my new website for Physicians and Patients interested in Still’s disease (systemic juvenile idiopathic arthritis), periodic fever syndromes and autoinflammatory diseases. Check out the cool AOSD Diagnosis Calculator!

Links:

Dr. John Cush RheumNow ( View Tweet)

Day 2 of the NIH Symposium on Autoinflammatory and immune-dysregulatory Diseases - 90 World experts on IL-1 mediated autoinflammatory diseases, autoinflammatory Type-I interferonopathies, MAS/HLH, LIVE STREAMING here>> https://t.co/WQjtS1JJue

Links:

Dr. John Cush RheumNow ( View Tweet)

RCT of 139 knee OA pts given either curcumin 500-mg tid or diclofenac 50-mg bid. At days 14 and 28 both had similar improvement in pain and KOOS score; but curcumin had better tolerance, less GI sxs and H2 blocker use. https://t.co/tcsDQWQOMg

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective review of US-guided Synovial Biopsies performed (clinical practice n=52, research n=12) - syn tissue obtained in 88%. Utility/impact was good (37% Dx impact, >95% PPV or NPV for infection & research 92% success. https://t.co/A7vzIHnKH1

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 1272 RA pts, 69.5% were seropositive. Seropositive RA patients had two-fold increased risk for abnormalities on PFTs (ORs ranging from 2.48 RLD, 3.12 COPD & 2.30 DLCO abnl; associations were stronger for RF+ than for CCP+. https://t.co/RQ5GgoGqwA

Links:

Dr. John Cush RheumNow ( View Tweet)

Thurs 8AM - start of the 2nd NIH Symposium on Autoinflammatory and immune-dysregulatory Diseases - World experts on IL-1 mediated autoinflammatory diseases, autoinflammatory Type-I interferonopathies, MAS/HLH, LIVE STREAMING AT 8AM EST https://t.co/XJ4EOIXyYm

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective review of temporal artery biopsies from Johns Hopkins Wilmer Eye institute from 2007-17 shows the adjusted incidence rate of Bx+ GCA was 3.1 (1.0-5.2) in blacks and 3.6 ( 2.5-4.7) per 100 000 white patients; higher in women (1.9x vs Men) https://t.co/MeO9cBqovg

Links:

Dr. John Cush RheumNow ( View Tweet)

CMAJ reports on a case controlled study of >3000 pts shows GERD to be a a risk factor for TMJ disorders (OR 2.74; 1.88 to 3.98) with such patients having a higher rates of somatization, anxiety and sleep disorders. https://t.co/jrTPCOVouI

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×